Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and EfficacyLexaria Bioscience Corp. (NA...
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastroint...
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted sid...
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotineKELOWNA, BC / ACCESS Newswire / J...
KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance pe...
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight lossKELOWNA, BC / ACCESSWIRE / December...
Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutideKELOWNA, BC ...
